Therma Bright Congratulates John Patton, PhD of InStatin on Receiving the Prestigious Charles G. Thiel Award
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) congratulates John Patton, Ph.D, Chairman of their strategic investment partner InStatin, on receiving the prestigious Charles G. Thiel Award for outstanding research in respiratory drug delivery. Patton, a renowned biotechnology scientist, has a track record of successful ventures including co-founding Inhale/Nektar and Halozyme. InStatin is developing a novel inhaled statin solution for treating chronic lung conditions like asthma and COPD. Therma Bright owns 17% of InStatin, with potential for increased ownership. The global asthma treatment market is projected to reach $30.1 billion by 2030. Therma Bright also holds over 60% of InVixa shares, which is developing inhaled statins for acute lung disease.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) congratula John Patton, Ph.D, Presidente del loro partner strategico InStatin, per aver ricevuto il prestigioso Charles G. Thiel Award per l'eccellente ricerca nella somministrazione di farmaci respiratori. Patton, rinomato scienziato biotecnologico, ha un curriculum di successi tra cui la co-fondazione di Inhale/Nektar e Halozyme. InStatin sta sviluppando una nuova soluzione di statina inalata per trattare condizioni polmonari croniche come asma e BPCO. Therma Bright possiede il 17% di InStatin, con potenziale per aumentare la propria partecipazione. Si prevede che il mercato globale del trattamento dell'asma raggiunga $30,1 miliardi entro il 2030. Therma Bright detiene anche oltre il 60% delle azioni di InVixa, che sta sviluppando statine inalate per malattie polmonari acute.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) felicita a John Patton, Ph.D, Presidente de su socio estratégico InStatin, por haber recibido el prestigioso Charles G. Thiel Award por su destacada investigación en la entrega de medicamentos respiratorios. Patton, un famoso científico en biotecnología, tiene un historial de aventuras exitosas, incluyendo la co-fundación de Inhale/Nektar y Halozyme. InStatin está desarrollando una nueva solución de estatina inhalada para tratar condiciones pulmonares crónicas como el asma y la EPOC. Therma Bright posee el 17% de InStatin, con potencial para aumentar su participación. Se proyecta que el mercado global de tratamiento del asma alcanzará $30.1 mil millones para 2030. Therma Bright también posee más del 60% de las acciones de InVixa, que está desarrollando estatinas inhaladas para enfermedades pulmonares agudas.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF)는 전략 투자 파트너 InStatin의 John Patton, Ph.D 의장이 호흡기 약물 전달 분야에서 뛰어난 연구로 Charles G. Thiel Award를 수상한 것을 축하합니다. Patton은 유명한 생명공학 과학자로, Inhale/Nektar 및 Halozyme의 공동 창립을 포함하여 성공적인 경력을 가지고 있습니다. InStatin은 천식 및 COPD와 같은 만성 폐 질환 치료를 위한 새로운 흡입형 스타틴 솔루션을 개발하고 있습니다. Therma Bright는 InStatin의 17%를 소유하고 있으며, 소유권을 늘릴 가능성이 있습니다. 전 세계 천식 치료 시장은 2030년까지 301억 달러에 이를 것으로 예상됩니다. Therma Bright는 또한 급성 폐 질환에 대한 흡입형 스타틴을 개발 중인 InVixa의 60% 이상의 지분을 보유하고 있습니다.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) félicite John Patton, Ph.D, Président de leur partenaire d'investissement stratégique InStatin, pour avoir reçu le prestigieux Charles G. Thiel Award pour sa recherche exceptionnelle sur l'administration de médicaments respiratoires. Patton, un scientifique renommé en biotechnologie, a un parcours d'aventures réussies, notamment la co-fondation d'Inhale/Nektar et de Halozyme. InStatin développe une nouvelle solution de statine inhalée pour traiter des affections pulmonaires chroniques telles que l'asthme et la BPCO. Therma Bright détient 17 % d'InStatin, avec un potentiel pour augmenter cette participation. Le marché mondial des traitements de l'asthme devrait atteindre 30,1 milliards de dollars d'ici 2030. Therma Bright détient également plus de 60 % des actions d'InVixa, qui développe des statines inhalées pour les maladies pulmonaires aiguës.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) gratuliert John Patton, Ph.D, dem Vorsitzenden ihres strategischen Investmentpartners InStatin, zur Verleihung des prestigeträchtigen Charles G. Thiel Award für herausragende Forschung im Bereich der Atemwegsmedikamentenabgabe. Patton, ein angesehener Biotechnologe, hat eine Erfolgsbilanz mit Unternehmungen wie der Mitbegründerin von Inhale/Nektar und Halozyme. InStatin entwickelt eine neue inhalierte Statinlösung zur Behandlung chronischer Lungenerkrankungen wie Asthma und COPD. Therma Bright besitzt 17% von InStatin, mit dem Potenzial für eine Erhöhung des Anteils. Der globale Markt für Asthmabehandlungen wird voraussichtlich bis 2030 auf 30,1 Milliarden Dollar anwachsen. Therma Bright hält auch über 60% der Anteile von InVixa, die inhalierte Statine für akute Lungenerkrankungen entwickelt.
- Strategic investment partner's chairman received prestigious award in respiratory drug delivery
- InStatin developing promising inhaled statin solution for asthma and COPD treatment
- Therma Bright owns 17% of InStatin with potential for increased ownership
- Global asthma treatment market projected to reach $30.1 billion by 2030
- Therma Bright holds over 60% of InVixa shares, developing inhaled statins for acute lung disease
- None.
Chairman of Therma Bright's Strategic Investment Partner Recognized for Outstanding Research and Discovery in Respiratory Drug Delivery
Toronto, Ontario--(Newsfile Corp. - September 4, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in cutting-edge diagnostic and medical device technologies, extends its congratulations to strategic investment partner InStatin's John Patton, Ph.D on receiving the prestigious Charles G. Thiel Award for outstanding research and discovery in respiratory drug delivery (RDD).
John Patton, Ph.D, a renowned biotechnology scientist, Chairman of InStatin and Head of the Scientific Advisory Board (SAB) for global leader Kindeva Drug Delivery (KDD), was honored at the Respiratory Drug Delivery Conference. The Charles G. Thiel Award, presented every two years by fellow scientists during the Conference, recognizes one individual for their pioneering and significant advancements in the science and technology of respiratory drug delivery.
Before InStatin, John held senior leadership roles and served on the boards of several prominent companies. He co-founded Inhale/Nektar (NKTR) in 1990, which achieved a
"We are thrilled to congratulate John on this well-deserved and prestigious award for his remarkable contributions to respiratory drug delivery (RDD) systems," said Rob Fia, CEO of Therma Bright. "John's achievements are clearly demonstrated by the advancements he and the InStatin team have made with their novel inhaled statin solution for treating and managing chronic lung conditions, such as asthma and chronic obstructive pulmonary disease (COPD). We're honored to be working with such a well-respected and recognized leader in the space, who has achieved several successful M&A exits."
InStatin's innovative statin inhalant solution has shown promising results in laboratory tests, and the Company is now moving forward with preclinical studies in preparation for Phase 1 human trials. Both InStatin and its investment partner, Therma Bright, are enthusiastic about the potential success of this groundbreaking inhalant solution for asthma treatment, which is projected to reach a global market size of USD
Additionally, Therma Bright and InStatin are progressing forward with InVixa, which is developing inhaled statins to prevent and treat acute lung disease. As announced on September 27, 2023, Therma Bright holds over
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as progressing clinical trials at InStatin, and related information as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-Looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222080
FAQ
What award did John Patton, Chairman of InStatin, receive?
What is InStatin developing and for which conditions?
What percentage of InStatin does Therma Bright (TBRIF) own?
What is the projected market size for asthma treatment by 2030?
What is Therma Bright's (TBRIF) involvement with InVixa?
